Goldman Sachs
PARN

Goldman Sachs’s Parnell Pharmaceuticals Holdings Ltd PARN Stock Holding History

Goldman Sachs’s Portfolio PARN Stock Details PARN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,451
Closed -$7K – 7304
2016
Q4 		$7K Sell
10,451
-444
-4% -$529 ﹤0.01% 6803
2016
Q3 		$15K Sell
10,895
-600
-5% -$928 ﹤0.01% 6824
2016
Q2 		$19K Sell
11,495
-4,383
-28% -$8.06K ﹤0.01% 6743
2016
Q1 		$34K Sell
15,878
-17,983
-53% -$49.6K ﹤0.01% 6588
2015
Q4 		$131K Sell
33,861
-2,941
-8% -$11.2K ﹤0.01% 6022
2015
Q3 		$127K Sell
36,802
-3,190
-8% -$13.5K ﹤0.01% 6329
2015
Q2 		$198K Sell
39,992
-5,408
-12% -$23.9K ﹤0.01% 6160
2015
Q1 		$223K Sell
45,400
-700
-2% -$3.24K ﹤0.01% 5926
2014
Q4 		$191K Buy
+46,100
New +$209K ﹤0.01% 6194

Other funds holding PARN

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Goldman Sachs's PARN Position: Q1 2017 in Review

Goldman Sachs sold out of Parnell Pharmaceuticals Holdings Ltd (PARN) in Q1 2017, closing a stake of 10,451 shares — an estimated $7K sold.

Goldman Sachs first reported a position in PARN in Q4 2014 and held it in 9 quarters. The position peaked at $223K in Q1 2015. 2 funds tracked by Wall St. Rank hold PARN as of Q1 2017.

  • Goldman Sachs reported no remaining Parnell Pharmaceuticals Holdings Ltd position as of Q1 2017 after selling out during the quarter.
  • Goldman Sachs sold 10,451 Parnell Pharmaceuticals Holdings Ltd shares in Q1 2017, an estimated $7K.
  • Goldman Sachs first reported a position in Parnell Pharmaceuticals Holdings Ltd in Q4 2014 and held it in 9 quarters.
  • Goldman Sachs's Parnell Pharmaceuticals Holdings Ltd position peaked at $223K in Q1 2015.
  • 2 funds tracked by Wall St. Rank held Parnell Pharmaceuticals Holdings Ltd as of Q1 2017.

Based on Goldman Sachs's 13F filing for Q1 2017, filed 15 May 2017.